EpiPen generic available this week
The first generic for EpiPen will be available at pharmacies this week, according to a press release from the manufacturer, Mylan. The auto-injector will be sold in packs of two and cost $300 at wholesale, half the price of the comparable name brand product.
In related news, Adamis Pharmaceuticals’ epinephrine auto-injector moved one step closer to becoming available to the public.
Mylan’s CEO said the generic is taken the same way, has the same device functionality and drug formulation as the EpiPen auto-injector, adding the company’s action is the first of its kind.
“While it is important to understand the outdated and complex system that determines what someone pays for medicine in the U.S., hardworking families don’t need an explanation, they need a solution,” Heather Bresch, Mylan CEO, said in the release. “This is why we took decisive action with our EpiPen product and have launched the first generic version at half the [wholesale acquisition cost] price. This unprecedented action, along with the enhancements we made to our patient access programs, will help patients and provide substantial savings to payors.”
Mylan had come under criticism after the price of the EpiPen increased 500% since 2007. At a Congressional hearing this past September, lawmakers accused the company of raising the price on the name brand version because there was no competition. At that time, Bresch said the company only made about $50 profit per pen.
For additional strategies clinicians can employ to help their patients deal with EpiPen’s price spike, read more here.
Since that hearing, kaleo announced plans to reintroduce AUVI-Q in early 2017, and just last week, Adamis Pharmaceuticals resubmitted its New Drug Application to the FDA, in an effort to bring its own epinephrine pre-filled syringe to market. According to the company, the resubmission addresses the FDA’s request from June to expand its Human Factors study (patient usability) and reliability study (product stress testing).
“With all of the recent news regarding products in the anaphylaxis market, we believe our product, now so, more than ever, can be a part of the potential solution for patients and payors as there is an obvious need for a low-cost therapeutic alternative like our [pre-filled syringe],” Dennis J. Carlo, PhD, president and CEO of Adamis, said in a press release. “I was encouraged by the results of the Human Factors study in that it showed our product to be intuitive in its use. In addition, based on what we have seen, we believe that many individuals would prefer our product over the EpiPen.”
Disclosure: Bresch is employed by Mylan; Carlo is employed by Adamis.